Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Merck’s keystone immunotherapy Keytruda has won yet another lung cancer approval in Europe, this time as the first line of defense for patients with metastatic squamous non-small cell lung cancer (NSCLC), on the basis of trial data that showed the drug — as part of a chemotherapy combo — cut the risk of death by 36% versus chemotherapy alone.